What are the differences in how to take tucatinib and precautions?

With the continuous progress of targeted therapy, Tucatinib (Tucatinib), a new generation oral tyrosine kinase inhibitor for the treatment of HER2 positive advanced breast cancer, has been approved for marketing in many countries. Its combined use with trastuzumab and capecitabine has significantly prolonged the progression-free survival of patients, especially bringing a therapeutic breakthrough to patients with brain metastases. However, to fully realize the efficacy of tucatinib, it is equally important to take it correctly and to be highly vigilant about potential risks. The following will be expanded from two dimensions - "how to take" and "precautions" to provide practical guidance for patients and family members.

First of all, from the perspective of how to take it, tucatinib is an oral small molecule targeted drug. The recommended dose is 300mg twice a day, which means taking two 150 tablets at one time. This usage requires patients to take it at a fixed time in the morning and evening every day, with an interval of about 12 hours. Compared with other anti-cancer drugs that require intravenous administration, tucatinib’s oral administration method is more convenient and suitable for long-term home treatment. In addition, tucatinib can be taken with food or on an empty stomach and is not affected by diet. However, clinical practice experience shows that taking it after meals can help reduce gastric discomfort and be more easily tolerated by patients.

If you miss a dose when taking medicine, you need to be careful in how you handle it. If it is more than 8 hours before the next dose, you can take it in time; but if it is close to the next dose, you should skip it. It is not recommended to take twice the dose at one time to make up for the missed dose. This principle helps avoid excessive fluctuations in drug concentration and reduces the risk of side effects. It is important to note that tucatinib is usually used in combination with trastuzumab and capecitabine, so patients need to reasonably plan the taking time of the three drugs every day to avoid omissions or duplications.

In terms of precautions, the first thing that should be paid attention to is liver function monitoring. Tucatinib is mainly metabolized by the liver in the body, so it has a certain impact on liver function. Some patients may experience hepatotoxic reactions such as elevated transaminases and abnormal bilirubin during medication. For this reason, it is recommended that patients undergo basic liver function tests before initiating treatment and then retest every two to four weeks. Once obvious liver function abnormalities are found, doctors may recommend reducing the dose, suspending or even permanently discontinuing the drug.

Drug interactions are also an important aspect that should not be ignored when using tucatinib. Tucatinib is a substrate of the CYP3A4 enzyme system and also affects the metabolism of other drugs. Strong CYP3A4 inhibitors (such as ketoconazole) or inducers (such as rifampicin) will significantly change the plasma concentration of tucatinib, resulting in weakened efficacy or increased toxicity. Therefore, you should avoid taking these drugs together while taking tucatinib, and report all prescription, over-the-counter, or herbal supplements you are taking to your doctor in advance.

Tucatinib is clearly contraindicated for pregnant and lactating women. Animal studies have shown that this drug may cause harm to the fetus, so female patients must use effective contraception while taking the drug and continue to use contraception for at least seven days after the end of treatment. In case of unwanted pregnancy, stop taking the medicine immediately and consult your doctor. For women who are breastfeeding, although there is currently no clear evidence on whether tucatinib is excreted through breast milk, it is recommended to completely avoid use during breastfeeding based on the potential risks.

Management of side effects is also an important part of the tucatinib considerations. Common adverse reactions include diarrhea, nausea, fatigue, decreased appetite, and hand-foot syndrome. Among them, diarrhea is more common and usually occurs in the early stages of treatment. It is recommended that patients use drugs such as loperamide to relieve symptoms under the guidance of a doctor; if the diarrhea reaches grade 3 or above, tucatinib may need to be suspended and gradually resume low-dose use after symptoms improve. Hand-foot syndrome is usually associated with capecitabine, but the combined use of tucatinib may increase its frequency. If pain, erythema, or peeling occurs, it should be treated promptly to avoid delaying treatment.

From the perspective of long-term management, patients need to undergo regular physical examinations and imaging evaluations during the use of tucatinib, including liver and kidney function, electrolytes, electrocardiogram and tumor control progress. Maintaining close communication with your doctor and dynamically adjusting the dose according to your physical condition is an important strategy to ensure the smooth progress of treatment.

Generally speaking, the method of taking tucatinib is relatively clear, with regular twice-daily dosing and no dietary restrictions, making the patient's compliance high. The precautions are relatively complex and involve many aspects such as liver function, drug interactions, adverse reaction management, and drug contraindications for special groups. A correct understanding of the difference between the two can help patients obtain curative effects while minimizing risks, and achieve the treatment goal of long-term stable disease control.

Reference materials:https://www.drugs.com/